UCB agreed to buy Neurona for up to $1.2 billion, adding seizure cell therapy ambitions to its predominantly small-molecule neurology portfolio. UCB said the acquisition is intended to diversify its epilepsy pipeline with a potentially one-off therapy in early testing. The deal reflects continued appetite for platform-style growth in neurological disease—where symptom control is giving way to disease-modifying approaches aimed at persistent seizure control. UCB framed the transaction as strategic expansion beyond its existing assets. For investors and partners, the price cap structure highlights how biotech is increasingly pricing clinical uncertainty while still securing exposure to high-upside regenerative and cell-therapy modalities.